kidney and renal diseases therapeutics market to 2017

1. Kidney and Renal Diseases Therapeutics Market to 2017

2. The Kidney and Renal Diseases Therapeutics Market is Forecast to Show Moderate Growth Until 2017 GBI Research’s analysis suggests that the global kidney and renal diseases therapeutics market was worth $50.3 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.5% for the next seven years, to reach $73 billion by 2017. The global market revenues are expected to increase due to the introduction of new therapies which are currently in the regulatory filing stage, and those in the later stages of development. These drugs include antioxidant inflammatory modulators, metal-free phosphate binders with improved safety and efficacy, nutritional supplements and iron replacement therapies. Competition among Marketed Products is Weak GBI Research analyzed the current competitive landscape for kidney and renal disease drugs and found the competition to be weak. There are more than 12 marketed products for the treatment of CKD, including angiotensin II receptor blockers (ARB), Angiotensin Converting Enzyme (ACE) inhibitors, phosphate binders, Erythropoietin (EPO) and iron replacement products. Although these products are moderately effective in controlling the progression of CKD, the serious adverse effects of these products have resulted in the discontinuation of therapies amongst patients. The market is in need of a first-in-class product which is efficient in slowing down the progression of CKD.

3. Poor Safety Profiles of Existing Therapies Create Unmet Needs That Attract Investment in the Pipeline GBI Research has found that the global kidney and renal disease therapeutics market is highly lucrative, as there is a substantial amount of unmet need to be satisfied with respect to the safety of medications. Serious adverse events associated with lanthanum carbonate, sevelamer carbonate, sevelamer hydrochloride and other phosphate binders create a need for products with better safety profiles and higher efficacy. In addition, the dosing regimen of the products is highly prohibitive for patients to remain on long-term treatment. As a result of discontinuation, only half of the patients meet the hyperphosphatemia treatment guidelines required for slowing down the disease progression. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017-Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-and-to-Create-Opportunities-for-Growth&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report GBI Research, the leading business intelligence provider, has released its latest research, “Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth”, which provides insights into the global kidney and renal diseases therapeutics market and market forecasts until 2017. The report provides an.

4. in-depth analysis of the top four therapeutic indications of kidney and renal diseases, which includes chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury. The report also examines the global kidney and renal disease treatment usage patterns for the covered indications. In addition, the report also includes insights into the kidney and renal diseases R&D pipeline. GBI Research analysis shows that the overall global kidney and renal diseases market for the four indications, chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury was valued at $50.3 billion in 2010. The market is expected to witness growth at a CAGR of 5.5% for the forecast period, and will reach $73 billion by 2017. The global market revenues are expected to increase due to the introduction of new therapies which are currently in the regulatory filing stage, and those in the later stages of development. These drugs include antioxidant inflammatory modulators, metal-free phosphate binders with improved safety and efficacy, nutritional supplements and iron replacement therapies. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017-Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-and-to-Create-Opportunities-for-Growth&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

5. Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@gbiresearch.com] North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782